1Dillman RO.Radio labeled anti-CD20 monoclonal antibodiesfor the treatment of B-cell lymphoma.J Clin Oncol,2002,20:3454.
2couturier O faivre C hauver A filippovich Ⅳ et al Validation of 213 Bi-alpha radioimmunotherapy for multiple myeloma[J].Cli Cancer Res.1999.5 (10 supple) ;3165-3170.
9Nishihara T.Sawada T.Yamamoto A et al.Antibody dependentcytotoxicity mediated by chimeric monoclonal antibody Nd2 andexperimental immunotherapy for pancreatic cancer[J].Jpn Cancer Res,2000,91 (8):817-824.
10Witzig TE,White CA,Wiseman GA,et al.Phase1/11trial ofIDECY2B8 radioimmunotherapy for treatment or refractory CD20(+)Bcellnon-Hodgkin's lymphoma.J Clin oncol,1999,17 (12):3793-3803.
9Jankowitz R, Judith J, Samuel A, et al. Anaphylaxis after administration of ibritumomab tiuxetan for follicular non-Hodgkin lymphoma[J]. Clinical Nuclear Medicine, 2008,22 (33) :94- 96.
10Vose JM, Coleher D, Gobar L, et al. Phase Ⅰ/Ⅱ trial of multiple dose ^131I odine-MAb LL2 (CD22) in patients with recurrent non-Hodgkin's lymphoma [J]. Leuk Lymphoma, 2000,3:91 - 101.